Balyasny Asset Management LLC Syndax Pharmaceuticals Inc Transaction History
Balyasny Asset Management LLC
- $61.9 Billion
- Q2 2025
A detailed history of Balyasny Asset Management LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 126,145 shares of SNDX stock, worth $2.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,145
Previous 1,817,009
93.06%
Holding current value
$2.04 Million
Previous $22.3 Million
94.71%
% of portfolio
0.0%
Previous 0.04%
Shares
12 transactions
Others Institutions Holding SNDX
# of Institutions
248Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$138 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$128 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$93.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$81.5 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$65.8 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $916M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...